Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Epratuzumab in Systemic Lupus Erythematosus
NCT00382837 · UCB Pharma · PHASE3 · withdrawn · last registry update 2014-05-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, UCB Pharma |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD22 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-04-28Also stopped (withdrawn): National Cancer Institute (NCI), BL22 immunotoxin (NCT00024115)
- 2015-03-26Results posted on the registry: Children's Oncology Group, L-asparaginase + doxorubicin hydrochloride (NCT00098839)
- 2015-03-24Results posted on the registry: Alliance for Clinical Trials in Oncology, epratuzumab + rituximab (NCT00301821)
- 2014-07-24Results posted on the registry: Alliance for Clinical Trials in Oncology, epratuzumab + rituximab (NCT00553501)
- 2014-05-22Also stopped (terminated): M.D. Anderson Cancer Center, Epratuzumab + Fludarabine (NCT00941928)
- 2014-01-03Results posted on the registry: SWOG Cancer Research Network, epratuzumab + clofarabine (NCT00945815)
- 2013-08-28Results posted on the registry: M.D. Anderson Cancer Center, Epratuzumab + Fludarabine (NCT00941928)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision